Back to Search
Start Over
SARS CoV-2 Genomic Characteristics and Clinical Impact of SARS-CoV-2 Viral Diversity in Critically Ill COVID-19 Patients: A Prospective Multicenter Cohort Study
- Source :
- Viruses; Volume 14; Issue 7; Pages: 1529, Viruses, Viruses, MDPI, 2022, 14 (7), pp.1529. ⟨10.3390/v14071529⟩, Viruses, 2022, 14 (7), pp.1529. ⟨10.3390/v14071529⟩
- Publication Year :
- 2022
- Publisher :
- Research Square Platform LLC, 2022.
-
Abstract
- Background: SARS-CoV-2 variant of concern (VOC) α spread worldwide, including in France, at the beginning of 2021. This variant was suggested to be associated with a higher risk of mortality than other variants. Little information is available in the subset of patients with severe disease admitted in the intensive care unit (ICU). We aimed to characterize the genetic diversity of SARS-CoV-2 variants isolated from patients with severe COVID-19 in order to unravel the relationships between specific viral mutations/mutational patterns and clinical outcomes.Methods: Prospective multicentre observational cohort study. Patients aged ≥18 years admitted in 11 ICUs from Great Paris area hospitals between October 1, 2020, and May 30, 2021 (before the introduction of VOC δ (B.617.2) in France) for acute respiratory failure (SpO2≤90% and need for supplemental oxygen or ventilator support) were included. SARS-CoV-2 infection, determined by RT-PCR testing. The primary clinical endpoint was day-28 mortality. Full-length SARS-CoV-2 genomes were sequenced by means of next-generation sequencing (Illumina COVIDSeq).Results: 413 patients were included, 183 (44.3%) had been infected with pre-existing variants, 197 (47.7%) with variant α (B.1.1.7), and 33 (8.0%) with other variants. Patients infected with pre-existing variants were significantly older (64.9±11.9 vs 60.5±11.8 years; p=0.0005); they had significantly more frequent COPD (11.5% (n=21/183) vs 4.1% (n=8/197); p=0.009), and higher SOFA score (4 [3-8] vs 3 [2-4]; 0.0002). Day-28 mortality was not different between patients infected with pre-existing, α (B.1.1.7) or other variants (31.1% (n=57/183) vs 26.2% (n=51/197) vs 30.3% (n=10/33), respectively; p=0.550). There was no association between day-28 mortality with a specific variant or the presence of specific mutations in SARS CoV-2 genome, including 17 mutations selected in the spike protein and all 1017 non-synonymous mutations detected throughout the entire viral genome.Conclusions: At ICU admission, patients infected with pre-existing variants had a different clinical presentation from those infected with variant α (B.1.1.7) and other variants later in the course of the pandemic, but mortality did not differ between these groups. There was no association between a specific variant or SARS CoV-2 genome mutational pattern and day-28 mortality.
- Subjects :
- [SDV.MP.VIR] Life Sciences [q-bio]/Microbiology and Parasitology/Virology
COVID-19
SARS-CoV-2
variant of concern
acute respiratory failure
intensive care unit
Adult
Adolescent
Critical Illness
Genomics
Infectious Diseases
Virology
[SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology
Humans
Prospective Studies
Subjects
Details
- ISSN :
- 19994915
- Database :
- OpenAIRE
- Journal :
- Viruses; Volume 14; Issue 7; Pages: 1529, Viruses, Viruses, MDPI, 2022, 14 (7), pp.1529. ⟨10.3390/v14071529⟩, Viruses, 2022, 14 (7), pp.1529. ⟨10.3390/v14071529⟩
- Accession number :
- edsair.doi.dedup.....9ad3f77c7fdd4f96350cee2b62a9745f